Table 4.

TEAEs by cohort (any grade, ≥ 20% or grade ≥ 3, ≥ 10%)^a

RCC Cohort N = 39
TEAE	Any Grade (≥ 20%)	Grade ≥ 3 (≥ 10%)
Stomatitis	25 (64)	7 (18)
Diarrhea	22 (56)	5 (13)
Epistaxis	22 (56)	0
Anemia	19 (49)	10 (26)
Decreased appetite	17 (44)	0
Fatigue	16 (41)	1 (3)
Nausea	16 (41)	2 (5)
Asthenia	11 (28)	1 (3)
Cough	11 (28)	0
Thrombocytopenia	10 (26)	1 (3)
Vomiting	10 (26)	2 (5)
Edema peripheral	9 (23)	0
Dizziness	9 (23)	0
Rash maculo-papular	9 (23)	2 (5)
Blood creatinine increased	8 (21)	0
Hyperglycemia	8 (21)	6 (15)
Pyrexia	8 (21)	0
Hypertension	4 (10)	4 (10)
GC Cohort N = 46
TEAE	Any Grade (≥ 20%)	Grade ≥ 3 (≥ 10%)
Anemia	27 (59)	16 (35)
Diarrhea	25 (54)	2 (4)
Neutropenia	20 (43)	20 (43)
Decreased appetite	19 (41)	2 (4)
Nausea	17 (37)	1 (2)
Stomatitis	17 (37)	1 (2)
Fatigue	16 (35)	1 (2)
Vomiting	15 (33)	0
Alopecia	14 (30)	0
Asthenia	14 (30)	5 (11)
Febrile neutropenia	14 (30)	14 (30)
Abdominal pain	10 (22)	3 (7)
Constipation	10 (22)	0
Neutrophil count decreased	10 (22)	9 (20)
White blood cell count decreased	9 (20)	5 (11)
Neutropenic sepsis	5 (11)	5 (11)
Pneumonia	6 (13)	5 (11)
CRC Cohort N = 50
TEAE	Any Grade (≥ 20%)	Grade ≥ 3 (≥ 10%)
Dermatitis acneiform	38 (76)	12 (24)
Stomatitis	26 (52)	5 (10)
Dry skin	24 (48)	1 (2)
Diarrhea	23 (46)	3 (6)
Fatigue	20 (40)	2 (4)
Paronychia	19 (38)	1 (2)
Pruritus	16 (32)	1 (2)
Decreased appetite	14 (28)	1 (2)
Nausea	13 (26)	0
Palmar-plantar erythrodysaesthesia syndrome	13 (26)	3 (6)
Asthenia	11 (22)	3 (6)
Epistaxis	10 (20)	0

^aAdverse events listed in descending order based on any grade incidence

CRC colorectal carcinoma, GC gastric adenocarcinoma, RCC renal cell carcinoma, TEAE treatment-emergent adverse event